LMR Partners’s Sarepta Therapeutics SRPT Stock Holding History

LMR Partners’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.38M	Sell	155,200 -202,000	-57%	-$3.91M	0.01%	746
2025 Q4	$7.69M	Buy	357,200 +183,800	+106%	+$3.87M	0.01%	459
2025 Q3	$3.34M	Buy	173,400 +97,600	+129%	+$1.74M	0.01%	609
2025 Q2	$1.3M	Buy	+75,800	New	+$3.23M	0.01%	738
2024 Q4	–	Sell	-37,000	Closed	-$4.62M	–	1575
2024 Q3	$4.62M	Sell	37,000 -32,100	-46%	-$4.44M	0.04%	389
2024 Q2	$10.9M	Sell	69,100 -33,800	-33%	-$4.34M	0.09%	194
2024 Q1	$13.3M	Sell	102,900 -91,000	-47%	-$11.1M	0.14%	151
2023 Q4	$18.7M	Buy	193,900 +8,800	+5%	+$844K	0.21%	113
2023 Q3	$22.4M	Sell	185,100 -34,800	-16%	-$3.93M	0.25%	95
2023 Q2	$25.2M	Buy	+219,900	New	+$28.4M	0.28%	86

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LMR Partners's SRPT Position: Q1 2026 in Review

LMR Partners reduced its Sarepta Therapeutics (SRPT) stake by 52% in Q1 2026, selling an estimated $300K and leaving 14,524 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

LMR Partners first reported a position in SRPT in Q2 2018 and has held it in 18 quarters since. The position peaked at $12.8M in Q2 2018. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

LMR Partners held 14,524 shares of Sarepta Therapeutics worth $316K as of Q1 2026.
LMR Partners sold 15,476 Sarepta Therapeutics shares in Q1 2026, an estimated $300K.
Sarepta Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1134 holding.
LMR Partners first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 18 quarters since.
LMR Partners's Sarepta Therapeutics position peaked at $12.8M in Q2 2018.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.